GlassScriptPhysician profile
Michael A Fulop
NPI 1679589840
$2,984.42
in general payments reported to CMS, 2019-2025
16 companies · $165 in 2025
The $165 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $929 · 2020: $519 · 2021: $572 · 2022: $261 · 2023: $193 · 2024: $345 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $491.31 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $372.00 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $360.34 | 2019-2025 | Hetlioz, Fanapt |
| Janssen Pharmaceuticals, INC | $309.64 | 2019-2024 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $263.36 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $248.98 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $189.18 | 2019-2025 | Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $171.50 | 2019-2024 | Ingrezza |
| Alkermes, INC. | $161.52 | 2019-2023 | Aristada, Lybalvi |
| Lundbeck LLC | $134.62 | 2019-2022 | |
| Allergan, INC. | $82.99 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.15 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $38.54 | 2024-2025 | Cobenfy |
| Eisai INC. | $36.21 | 2020-2021 | |
| Almatica Pharma LLC | $28.46 | 2024 | Loreev Xr |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $24.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Fulop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.